Sherene Loi, MD, PhD
Advertisement
Articles by Sherene Loi, MD, PhD
21 Ribociclib (RIB) + Nonsteroidal Aromatase Inhibitor (NSAI) as Adjuvant Treatment in Patients (pts) With HR+/HER2– Early Breast Cancer (EBC): Final Invasive Disease-Free Survival (iDFS) Analysis From the NATALEE Trial
ByGabriel N. Hortobagyi, MD, FACP,Daniil Stroyakovskiy,Denise A. Yardley, MD,Chiun-Sheng Huang,Peter A. Fasching,John Crown,Aditya Bardia, MD, MPH, FASCO,Stephen Chia,Seock-Ah Im,Miguel Martin, MD, PhD,Sherene Loi, MD, PhD,Binghe Xu,Sara A. Hurvitz, MD,Carlos Barrios,Michael Untch, MD, PhD,Rebecca Moroose,Frances Visco,Federico Parnizari,Farhat Ghaznawi,Zheng Li,Sorcha Waters,Arunava Chakravartty,Dennis J. Slamon, MD, PhD
In this interview we discuss some of the novel therapeutics in development for HER2-amplified breast cancer.
The future role of immunotherapy in breast cancer is currently being actively investigated, so we anticipate that we will soon have further clues about the role of immunotherapy in breast cancer patients.
Advertisement
Latest Updated Articles
22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEEPublished: June 24th 2025 | Updated:
- Immune Targeting in Breast Cancer: In Whom and With What?
Published: May 15th 2015 | Updated:
Novel Therapies in Development for HER2-Amplified Breast CancerPublished: June 27th 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
MARIPOSA Final OS Results in Asia Population Yield Meaningful Improvement in EGFR NSCLC
2
Novel Treatment Displays Tolerability in Relapsed/Refractory B-Cell ALL
3
3 Things You Should Know About Future Directions for BsAbs and ADCs in NSCLC
4
Surveying the Treatment Landscape for EGFR-Mutated Lung Cancer
5
